Mino-50 (Minocycline)

Minocycline binds to the 30S ribosomal subunit of bacteria, blocking the addition of aminoacyl‑tRNA to the growing peptide chain. This inhibition of protein synthesis stops bacterial growth, producing a bacteriostatic effect against susceptible organisms.

The specific dose of Mino-50 is determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal or hepatic function. Typical adult regimens range from 100 mg to 200 mg once or twice daily, but exact dosing must follow the prescriber’s order.

Safety data for minocycline in pregnancy are limited, and the drug is classified as a pregnancy category with unknown risk. It is excreted in breast milk, so use during lactation should be considered only if the potential benefit outweighs the risk to the infant.

To order Mino-50, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Both minocycline and doxycycline belong to the tetracycline class and share a similar mechanism of action. Minocycline is more lipophilic, often achieving higher tissue concentrations, and may be preferred for acne or infections where better penetration is desired. Doxycycline generally has a longer half‑life, allowing once‑daily dosing, and may have a slightly lower risk of vestibular side effects.

Mino-50 should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Mino-50 is taken orally with a full glass of water. It may be taken with or without food, but taking it with food can reduce gastrointestinal upset. Swallow the tablet whole; do not crush or chew.

Serious adverse reactions include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, drug‑induced hepatitis, and intracranial hypertension (pseudotumour cerebri). Patients should seek immediate medical attention if they develop rash, blistering, persistent vomiting, severe headache, or visual changes.

Mino-50 should be avoided in individuals with a known hypersensitivity to minocycline or other tetracyclines, children under eight years of age, pregnant women unless clearly indicated, and patients with severe hepatic impairment. Caution is also advised for those with renal dysfunction or a history of intracranial hypertension.